Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Heron Therapeutics, Inc.

NASDAQ: HRTX · Life Sciences · 4 alerts · CIK 818033

Share price
$0.2843Close, Nov 16
Market cap
$54.1M
Shares outstanding
190.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Heron Therapeutics, Inc. filings on SEC EDGAR ↗

8:51 AM ET 10-Q
Financial Results

Heron Therapeutics Q3 2026 Results: Net Loss of $5.01M, Loss Narrows

Heron Therapeutics filed its 10-Q for the period ended September 30, 2026, reporting 190,273,587 shares of common stock outstanding. The filing highlights a pending Asset Sale to CorMedix and notes significant risks regarding the company's ability to continue as a going concern without additional funding.

Key figure
Net loss $5.01M
8:15 AM ET 8-K
Financial Results

Heron Therapeutics Financial Results

Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.

Counterparty
CorMedix Therapeutics
7:41 AM ET 8-K
Divestiture

Heron Therapeutics Divestiture to CorMedix Inc. for $145M

Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.

Value
$145M
Counterparty
CorMedix Inc.
5:00 PM ET 8-K
Licensing Deal

Heron Therapeutics Licensing Deal with Long Grove Pharmaceuticals, LLC

Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services. The agreement grants Heron an exclusive license to import, distribute, and market certain products in the U.S. in exchange for regulatory milestones, sales-based milestones, and royalty payments.

Counterparty
Long Grove Pharmaceuticals, LLC
Term
10 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.